In the current study, we successfully utilized a DNA vaccination strategy combining an antigen-specific DNA and DNA encoding CD40L to improve antigen-specific CD8+ T cell immune responses against endogenous tumor antigens. This evidence concerns the gene CD8A and neoplasm.